BERTIL LINDMARK

Calliditas Therapeutics

MARIA TÖRNSÉN

Calliditas Therapeutics has appointed Maria Törnsén as president, North America. Törnsén has over two decades of experience in the biopharmaceutical industry in senior commercial roles. She currently serves as a board member for Immunic Therapeutics. Prior to this, Törnsén served as chief commercial officer at Passage Bio and as senior vice president, general manager US at Sarepta Therapeutics, earlier in her career.

Informed Genomics

SIMON DAVIS

Informed Genomics has appointed Simon Davis as chief executive officer. Davis brings over two decades of experience within the life sciences and MedTech industry. He most recently served as commercial director at the company. Prior to this, Davis served as a commercial management consultant at Allington Associates, which followed on from his role as chief commercial officer
at Everything Genetic.

Mirum Pharmaceuticals

JOANNE QUAN

Mirum Pharmaceuticals has appointed Joanne Quan as chief medical officer. Quan brings over two decades of experience in leadership roles to her new position. She most recently served as chief medical officer at Nuvig Therapeutics. Prior to this, Quan served as chief medical officer at Modis Therapeutics. Earlier in her career, Quan served as vice president, new product clinical development at InterMune.

LifeArc

HEATHER MCKINNON

LifeArc has appointed Heather McKinnon as senior director for diagnostics and its opportunity assessment group. McKinnon brings over two decades of experience in drug discovery leadership. She was most recently executive director, integrated drug discovery at Syngene International. She was also joint head of drug discovery at Cancer Research UK Beatson Institute and served as research programme manager at Myeloma UK.

Revagenix

CRISTINA LARKIN

Revagenix has appointed Cristina Larkin to its board of directors. Larkin has over three decades of experience in biotechnology and pharmaceuticals. She currently serves as executive in residence at Columbia Technology Ventures. Prior to this, Larkin served as advisor and executive in residence at the Cleveland Clinic. Earlier in her career, she served as chief operating officer at Spero Therapeutics.

Revagenix

MICHAEL LAMPRECHT

Revagenix has appointed Michael Lamprecht to its board of directors. Lamprecht brings over a decade of drug development experience to his new position. He currently serves as an investment associate for Tenmile. Prior to this, he served as an entrepreneur in residence at Xora Innovation. Lamprecht also served as director, regulatory affairs at EpiBone and licensing lead at Cellanyx Diagnostics.

CatalYm

PETROS GRIVAS

CatalYm has appointed Petros Grivas to its scientific advisory board. Grivas brings a wealth of experience and high expertise in genitourinary cancers. He is currently the clinical director of the GU Cancers Program. Grivas also serves as a professor at the department of medicine, division and hematology, oncology, University of Washington and the clinical research division at Fred Hutchinson Cancer Center.

CatalYm

ANDREA NECCHI

CatalYm has appointed Andrea Necchi to its scientific advisory board. Necchi has a wealth of experience across multiple areas of oncology. He currently serves as associate professor of oncology at Vita-Salute San Raffaele University, director of genitourinary medical oncology at IRCCS San Raffaele Hospital and Scientific Institute in Milan. Necchi also serves as a board member of the EAU Research Foundation.